Veru: Q3 Earnings Insights

 

Shares of Veru VERU rose 13.2% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 40.00% over the past year to ($0.03), which beat the estimate of ($0.06).

Revenue of $17,656,000 rose by 71.05% from the same period last year, which beat the estimate of $14,100,000.

Looking Ahead

Veru hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 12, 2021

Time: 08:00 AM

ET Webcast URL: https://verupharma.com/investors/

Technicals

52-week high: $24.57

52-week low: $2.30

Price action over last quarter: Up 8.69%

Company Description

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!